创新药ETF天弘（517380）收涨2.24%，涨幅居创新药类ETF第1、全市场第12，机构：创新药仍将是医药投资的主线

Group 1 - The A-share and Hong Kong stock markets saw a strong performance in the innovative drug sector, with the Tianhong Innovative Drug ETF (517380) closing up 2.24%, ranking first among innovative drug ETFs and twelfth in the overall ETF market, with a trading volume exceeding 11 million yuan [1] - The Tianhong Innovative Drug ETF was launched in 2021 and tracks the "Hang Seng Shanghai-Shenzhen Hong Kong Innovative Drug Selected 50" index, providing comprehensive coverage of the innovative drug industry across A-shares and Hong Kong stocks [1] - Key stocks in the ETF included Ruizhi Pharmaceutical, which rose over 13%, along with other notable gainers such as Tigermed, Hutchison China MediTech, Federal Pharmaceutical, and Huahai Pharmaceutical [1] Group 2 - Hansoh Pharmaceutical announced a licensing agreement with Regeneron Pharmaceuticals for the global exclusive rights to develop, produce, and commercialize HS-20094, excluding mainland China, Hong Kong, and Macau, with an upfront payment of $80 million and potential milestone payments of up to $1.93 billion [2] - The innovative drug sector is expected to continue being a primary focus for pharmaceutical investments, driven by increasing policy support and a shift from quantity and speed to quality and innovation in Chinese innovative drugs [4] - The number of original research drugs entering clinical stages in China has reached 704, surpassing the United States and positioning China as the global leader in this area [3]